Peptide therapeutics: current status and future directions
Keld Fosgerau, Torsten Hoffmann
Drug Discovery Today · 2014 · 3,091 citationsOpen access
Abstract
Peptides are recognized for being highly selective and efficacious and, at the same time, relatively safe and well tolerated. Consequently, there is an increased interest in peptides in pharmaceutical research and development (R&D), and approximately 140 peptide therapeutics are currently being evaluated in clinical trials. Given that the low-hanging fruits in the form of obvious peptide targets have already been picked, it has now become necessary to explore new routes beyond traditional peptide design. Examples of such approaches are multifunctional and cell penetrating peptides, as well as peptide drug conjugates. Here, we discuss the current status, strengths, and weaknesses of peptides as medicines and the emerging new opportunities in peptide drug design and development.
Cite this paper
Fosgerau, K., & Hoffmann, T. (2014). Peptide therapeutics: current status and future directions. Drug Discovery Today, 20(1), 122–128. https://doi.org/10.1016/j.drudis.2014.10.003
Read it with every claim anchored
Add this paper to a project, ask questions of it, and get answers that point to the exact passage.
Start freeRelated papers
- Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.1979
- Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.1981
- Comprehensive molecular portraits of human breast tumours2012
- Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins.1986
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer1989
Metadata from OpenAlex (CC0). Citations are generated from the published record.